Functional brain connectome in posterior cortical atrophy

Migliaccio, Raffaella; Basaia, Silvia; Cividini, Camilla; Habert, Marie Odile; Kas, Aurélie; Montembeault, Maxime; Filippi, Massimo

doi:10.1016/j.nicl.2019.102100

Cited by 19 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typical topographic patterns of hypometabolism associated with AD, FTLD, and DLB are summarized in Table 1 . Patterns of hypometabolism tend to mirror clinical presentations, and might also help to support diagnostic work-up of atypical AD in the framework of posterior cortical atrophy [ 22 – 24 ] and primary progressive aphasia [ 25 ] (also reported in Table 1 ). Beyond the differential diagnosis with vascular dementia, [ 18 F]FDG-PET can also be used to help distinguish between cognitive impairment of degenerative diseases from nondegenerative origin, such as in traumatic brain injury (in correlation to MRI using PET/MRI device or fusion [ 26 ]), idiopathic normal pressure hydrocephalus (showing striatal hypometabolism with preserved cortical metabolism) [ 27 ], or depression.…”

Section: Clinical Indicationsmentioning

confidence: 99%

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

Guedj

Varrone

Boellaard

et al. 2021

Eur J Nucl Med Mol Imaging

140

View full text Add to dashboard Cite

The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations.

show abstract

Section: Clinical Indicationsmentioning

confidence: 99%

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

Guedj

Varrone

Boellaard

et al. 2021

Eur J Nucl Med Mol Imaging

140

View full text Add to dashboard Cite

show abstract

“… 110 In addition, the combination of tau and FDG-PET with functional MRI would enable further insight into the consequences of pathological deposits on functional networks and to better understand the pathological course of AD. 111 Future studies need to highlight the crucial role of combining different MRI techniques together with other imaging modalities, in order to study different aspects of neurodegeneration.…”

Section: Resultsmentioning

confidence: 99%

An update on magnetic resonance imaging markers in AD

Leocadi

Canu

Calderaro

et al. 2020

Ther Adv Neurol Disord

Self Cite

View full text Add to dashboard Cite

The purpose of the present review is to provide an update of the available recent scientific literature on the use of magnetic resonance imaging (MRI) in Alzheimer’s disease (AD). MRI is playing an increasingly important role in the characterization of the AD signatures, which can be useful in both the diagnostic process and monitoring of disease progression. Furthermore, this technique is unique in assessing brain structure and function and provides a deep understanding of in vivo evolution of cerebral pathology. In the reviewing process, we established a priori criteria and we thoroughly searched the very recent scientific literature (January 2018–March 2020) for relevant articles on this topic. In summary, we selected 73 articles out of 1654 publications retrieved from PubMed. Based on this selection, this review summarizes the recent application of MRI in clinical trials, defining the predementia stages of AD, the clinical utility of MRI, proposal of novel biomarkers and brain regions of interest, and assessing the relationship between MRI and cognitive features, risk and protective factors of AD. Finally, the value of a multiparametric approach in clinical and preclinical stages of AD is discussed.

show abstract

“…Atypical clinical presentations of AD are not uncommon and CSF biomarkers seem to offer a useful index for ante mortem identification of most such patients in routine practice, especially in cases mixed with vascular or Lewy-body pathology, and in some atypical presentations such as PPA, CBS, frontal dysexecutive and/or behavioural syndrome or PCA [28,[35][36][37][38][39][40][41][42][43][44][45][46][47][48]. It is unknown whether currently available treatments for AD have the same effectiveness in atypical as in typical amnestic presentations.…”

Section: Discussionmentioning

confidence: 99%

Atypical Presentations of Alzheimer’s Disease: Beyond Amnestic Dementia

Tsantzali¹,

Paraskevas²,

Paraskevas³

et al. 2020

CEI

View full text Add to dashboard Cite

Neuropathological and biomarker-based studies indicate that Alzheimer’s disease may sometimes present not with the typical amnestic dementia syndrome of the hippocampal type but with atypical clinical pictures. Atypical presentations include frontal dementia sometimes with additional behavioural component mimicking frontotemporal dementia, logopenic primary progressive aphasia and posterior cortical atrophy, while mixed presentations include patients with additional vascular or Lewy body pathology. More atypical presentations include non-logopenic (semantic, non-fluent agrammatic and unclassifiable) primary progressive aphasia, corticobasal syndrome and cases mixed with normal pressure hydrocephalus. Atypical clinical presentations of Alzheimer’s disease may be more common than previously thought. Cerebrospinal fluid levels of biomarkers such as amyloid beta peptide, hyperphosphorylated tau protein and total tau protein, may offer a useful tool for correct ante mortem identification of such patients, which is likely to affect therapeutic decisions.

show abstract

Functional brain connectome in posterior cortical atrophy

Cited by 19 publications

References 31 publications

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

An update on magnetic resonance imaging markers in AD

Atypical Presentations of Alzheimer’s Disease: Beyond Amnestic Dementia

Contact Info

Product

Resources

About